Leap Therapeutics Inc (NASDAQ: LPTX) has seen a rise in its stock price by 13.49 in relation to its previous close of 0.26. However, the company has experienced a -3.92% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-23 that Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder value CAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease.
Is It Worth Investing in Leap Therapeutics Inc (NASDAQ: LPTX) Right Now?
The 36-month beta value for LPTX is also noteworthy at -0.30. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for LPTX is 30.74M, and at present, short sellers hold a 5.19% of that float. The average trading volume of LPTX on July 01, 2025 was 1.35M shares.
LPTX’s Market Performance
LPTX stock saw a decrease of -3.92% in the past week, with a monthly decline of -20.78% and a quarterly a decrease of -6.22%. The volatility ratio for the week is 12.65%, and the volatility levels for the last 30 days are 12.46% for Leap Therapeutics Inc (LPTX). The simple moving average for the last 20 days is -18.26% for LPTX stock, with a simple moving average of -81.28% for the last 200 days.
Analysts’ Opinion of LPTX
Many brokerage firms have already submitted their reports for LPTX stocks, with Robert W. Baird repeating the rating for LPTX by listing it as a “Neutral.” The predicted price for LPTX in the upcoming period, according to Robert W. Baird is $1.25 based on the research report published on January 29, 2025 of the current year 2025.
Rodman & Renshaw gave a rating of “Buy” to LPTX, setting the target price at $8 in the report published on June 28th of the previous year.
LPTX Trading at -20.89% from the 50-Day Moving Average
After a stumble in the market that brought LPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.80% of loss for the given period.
Stock Fundamentals for LPTX
The total capital return value is set at -3.41. Equity return is now at value -202.81, with -149.01 for asset returns.
Based on Leap Therapeutics Inc (LPTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -384.82. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 11858.17.
Currently, EBITDA for the company is -66.97 million with net debt to EBITDA at 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.41.
Conclusion
In summary, Leap Therapeutics Inc (LPTX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
